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Abstract
Parasitic diseases have been known to cause pulmonary vascular lesions. Schistosomiasis is the most common parasitic disease associ-
ated with pulmonary arterial hypertension, although other trematodes have been implicated. Systematic evaluation of and interest in this
problem have been rekindled because of the current availability of pulmonary arterial hypertension treatment.
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Schistosomiasis
Schistosomiasis (or bilharzia, bilharziosis or snail fever) is a
parasitic disease caused by trematode ﬂatworms of the genus
Schistosoma. The parasites were ﬁrst identiﬁed in 1851 by
Theodor Bilharz, a German pathologist working in Egypt.
There are 24 species of Schistosoma, and they can be split
into four distinct groups on the basis of the compatibility of
species with particular snail host genera and geographical dis-
tribution, as well as common egg morphologies. Among
these species, six cause disease in humans, with the three
main species being Schistosoma mansoni, Schistosoma japonicum
and Schistosoma haematobium [1]. Some species also infect
wild animals and domestic stock (e.g. S. japonicum), and oth-
ers are primarily veterinary pathogens (Schistosoma bovis,
Schistosoma mattheii and Schistosoma curassoni) [2].
There is currently no vaccine available, and primary treat-
ment for human schistosomiasis is the drug praziquantel, which
is usually effective in a single dose. However, praziquantel does
not prevent re-infection, is inactive against juvenile schisto-
somes and has only a limited effect on already developed liver
and spleen lesions. Praziquantel is also limited by the emer-
gence of schistosome phenotypes that are resistant to this
drug [3]. Alternative treatments include oxamniquine [4,5].
In this review, we will concentrate on pulmonary and
inﬂammatory manifestations caused by Schistosoma infection,
even though the lung is a mandatory step in the parasite
cycle. These manifestations can be acute or chronic, depending
on the phase of the cycle. Morbidity resulting from chronic
manifestations is particularly severe and should be prevented
whenever possible.
Life cycle of schistosomes
Schistosomes have a vertebrate–invertebrate life cycle, in
which humans are a deﬁnitive host. The ﬁrst step in the cycle
is infection of a freshwater snail by the miracidium, a small,
free-living larva that swims and penetrates speciﬁc snail inter-
mediate hosts within 1–24 h. In the snail, miracidia transform
into the next larval stage, cercariae, which subsequently
emerge from the snail. The cercariae remain swimming in fresh
water using a whip-like tail (for a maximum of 48 h) at speeds
of about 4 m/h, and can penetrate the skin of people working
or bathing in the infected water in 3–5 min. Cercariae have
the ability to attach to human skin and, through secretion of
enzymes, break down skin proteins and invade the new host.
After penetration, they may remain in the skin for 1–2 days.
After infecting humans, cercariae shed their tails and become
schistosomula, which migrate in the venous circulation, pass
through the lungs, and home to their target organ, where they
mature and unite. A pair of worms, male and female, attaches
to the superior mesenteric veins (S. mansoni), the inferior
mesenteric and superior haemorrhoidal veins (S. japonicum) or
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the vesical plexus and veins draining the ureters (S. haematobium).
About 4–6 weeks after infection, schistosomes begin to pro-
duce eggs, and this continues for the parasite’s entire lifespan,
usually 3–5 years (about 300 eggs per day for S. mansoni and
up to 3000 eggs per day for S. japonicum). Eggs are excreted in
the faeces (S. mansoni and S. japonicum) or urine (S. haematobi-
um). Under optimal conditions, the eggs hatch within 30 min,
releasing miracidia. Nevertheless, many of the eggs remain
within the host, resulting in focal granulomatous reactions.
Eggs laid by S. mansoni and S. japonicum remain in the tissues
within the hepatic portal system, resulting in pre-hepatic ﬁbro-
sis and portal hypertension.
Chronic portal hypertension can result in the opening of
portocaval shunts, allowing eggs to migrate from the portal
system to the pulmonary parenchyma. Within the lungs, the
eggs induce an immune response, which similarly results in
severe granulomas. However, a unique pathology of pulmo-
nary arterial vascular remodelling is also manifested, resulting
in clinical pulmonary arterial hypertension (PAH) [1,6–8].
Epidemiology
Schistosomiasis affects over 200 million people worldwide,
resulting in more than 250 000 deaths and up to 4.5 million
disability-adjusted years lost annually [9–15]. The chronic
morbidity of schistosomiasis includes anaemia, fatigue, under-
nutrition and chronic pain. Schistosomiasis is endemic in 74
countries, including throughout Africa, Brazil, the Middle East
and Southeast Asia. Schistosomiasis is the third most common
parasitic disease worldwide after malaria and amoebiasis.
Cercariae are found in fresh water in endemic regions,
resulting in human infection in the context of daily activities,
including farming, walking, bathing and swimming. Despite
the availability of antihelminthic agents such as praziquantel,
endemic areas can have case-prevalence rates in excess of
50%. Treated individuals are re-infected upon re-exposure,
making the disease difﬁcult to completely eradicate. Socio-
economic development projects such as the construction of
dams, natural disasters, including ﬂooding, and poor sanitary
conditions all combine to result in high prevalence rates
within underdeveloped and developing regions [16].
Of all people infected with Schistosoma worldwide,
approximately 10% of those chronically infected with S. man-
soni develop hepatosplenic disease, resulting in pre-portal
ﬁbrosis and portocaval shunting, including oesophageal vari-
cies [17]. Approximately 10–20% of those with hepatosplenic
disease, or 2–5 million people worldwide, develop PAH, a
progressive and fatal illness [18]. This high prevalence makes
schistosomiasis one of the most common causes of PAH
worldwide [19], resulting in considerable mortality and mor-
bidity, although the precise disease burden is unknown.
Clinical manifestations of Schistosoma infection
Patients initially infected with Schistosoma develop a maculo-
papular rash at the site of parasite penetration within hours
of infection [20]. This reaction lasts for several days and then
spontaneously resolves as the cercariae transform into
schistosomula and move into the systemic venous system.
The rash, also called cercarial dermatitis, occurs more com-
monly in people infected for the ﬁrst time than in chronically
infected and re-infected individuals.
As the parasite embolizes through the systemic venous
circulation to the pulmonary arterioles, it causes a general-
ized inﬂammatory response in the host, termed Katayama
fever. This self-limiting syndrome is characterized by fevers,
chills, shortness of breath and a dry cough [21]. Physical
examination may reveal tender hepatomegaly and splenomeg-
aly [20]. Chest radiographs may show a patchy alveolar inﬁl-
trate. Laboratory studies reveal peripheral eosinophilia.
Katayama fever begins 2–12 weeks after primary infection,
and can last for several weeks, before spontaneous resolu-
tion as the parasite passes through the lungs and migrates
through the systemic arterial circulation to its target organ.
The symptoms of chronic Schistosoma infection depend on
the speciﬁc parasite and the severity of disease. Patients with
intestinal S. mansoni or S. japonicum infection can have
abdominal pain, diarrhoea and iron-deﬁciency anaemia, with
the resulting constitutional symptoms including weight loss,
undernutrition and chronic fatigue. Patients with hepatosplen-
ic disease have the symptoms of intestinal Schistosoma infec-
tion plus the symptoms resulting from pre-portal ﬁbrosis and
portal hypertension, including splenomegaly and the forma-
tion of oesophageal and haemorrhoidal varicies with resultant
bleeding (potentially massive and fatal). However, because the
disease remains pre-portal, cirrhosis does not generally
result. Patients with chronic S. haematobium infection have
symptoms resulting from chronic inﬂammation of the venous
plexus around the bladder, including haematuria, ﬁbrosis with
ureteral obstruction and nephrolithiasis, and squamous cell
carcinoma of the transitional epithelium of the bladder [22].
In patients with chronic Schistosoma infection, eggs can
embolize throughout the body, with focal granulomatous
reactions and symptoms that depend on the precise location
of deposition. One of the most sensitive locations is the cen-
tral nervous system, with the consequence of focal or gener-
alized tonic–clonic seizures or focal neurological deﬁcits
[20,23].
Schistosomiasis-associated PAH
PAH is one of the pulmonary manifestations in schistosomi-
asis, particularly in its hepatosplenic presentation. Portal
hypertension almost invariably precedes PAH in schistosomi-
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asis, establishing venous shunts between the portal and sys-
temic circulation, allowing the passage of schistosome eggs
from the liver to the lungs [24]. In one recent series of 65
patients, the incidence of PAH (pulmonary artery systolic
pressure >40 mmHg) in patients with hepatosplenic disease
referred to a gastroenterology clinic was 18.5% on echocar-
diography, and PAH was conﬁrmed in 7.7% by right heart
catheterization [25] (Loureiro et al., American Heart Associ-
ation, 2004, Abstract No. 2659, pp. III-572). Other reports
from two pulmonary referral centres in Brazil demonstrated
that, among all the patients, 30% had symptoms of PAH
associated with schistosomiasis [26]. Analysis of chest radio-
graphs revealed that among 115 schistosomiasis patients, 84
had radiographs compatible with cardiopulmonary abnormal-
ities, including 11 suggestive of PAH [27]. Portopulmonary
hypertension and PAH associated with schistosomiasis have
also been described in Africa [28].
Patients who develop schistosomiasis-associated PAH have
the signs and symptoms of this condition, primarily resulting
from progressive right heart failure. Initial symptoms include
dyspnoea, fatigue and exercise intolerance. As the disease pro-
gresses, patients can experience chest pain from right ventric-
ular angina and syncope caused by from depressed cardiac
output and low systolic blood pressure. Physical examination
may reveal a prominent pulmonic component second heart
sound (P2), right ventricular heave and digital clubbing.
Patients with frank right heart failure manifest cyanosis and
peripheral oedema or anasarca. Radiographs may reveal
cardiomegaly, particularly dilatation of the right ventricle and
right atrium, and enlarged pulmonary trunk and arteries, with
pruning of the distal vasculature (Fig. 1). Electrocardiography
typically shows right ventricular hypertrophy or strain and
right atrial enlargement, and may also reveal a right bundle
branch block. Echocardiography demonstrates right ventricu-
lar dilatation, potentially compressing the left ventricle with
septal bowing, usually accompanied by right atrial dilation, tri-
cuspid valve regurgitation and an increased pressure gradient
across the tricuspid valve. Finally, right heart catheterization
(when available) is used to conﬁrm the diagnosis of PAH in the
absence of an elevated pulmonary artery occlusion pressure.
Speciﬁc prognostic data from patients with schistosomia-
sis-associated PAH arelacking, but the prognosis is probably
similar to that with other forms of PAH, including idiopathic
PAH (IPAH). Patients with untreated IPAH usually die within
3–5 years after initial presentation, the lifespan being <1 year
in those with severe symptoms [29]. It is of note that
patients with varicial bleeding as a consequence of schistoso-
miasis portal hypertension who receive surgical portocaval
shunt therapy can have poor short-term outcomes, because
of the development of PAH [30].
Histopathology of schistosomiasis-associated PAH
The pulmonary histopathology of schistosomiasis-associated
PAH has similarities to and differences from other forms of
PAH that are more common in the developed world, most
classically IPAH. The pathology of IPAH includes focal altera-
tions in all layers of the arterial vasculature, including the
intima, media and adventitia. However, the precise distribu-
tion of lesions is not known, as both abnormal and normal
vasculature are often seen concurrently even in the same
specimen. Examples of vascular lesions seen at autopsy in a
patient who died of schistosomiasis-associated PAH are
shown in Fig. 2.
There are four types of intimal lesion: concentric thicken-
ing, eccentric thickening, plexiform, and dilated or angioma-
toid [31]. Lesions with concentric thickening have an onion
skin appearance, with multiple layers. Eccentric lesions may
result from old or chronic thrombus that has become largely
incorporated into the vessel wall. Plexiform lesions are focal
proliferations of endothelial cells resulting in focal tortuous
passages. Dilated or angiomatous lesions may be located
downstream of plexiform lesions resulting from the focal tur-
bulence in blood ﬂow.
The vascular media can be thickened in association with
or in locations distinct from the endothelial lesions. Most
severe forms of PAH, including that associated with schisto-
somiasis, are probably inﬂammatory in nature [32], with an
inﬂammatory inﬁltrate often being seen around the adventitia
of affected vasculature. Remarkably, there is evidence that
this inﬁltrate, and potentially many of the cells forming the
vascular media and intimal lesions, are derived from the
circulatory system [33,34].
FIG. 1. A chest radiograph of a 52-year-old man with schistosomia-
sis-associated pulmonary arterial hypertension, resulting in right ven-
tricular hypertrophy and a dilated pulmonary trunk. Reproduced
with permission from Safwat, PVRI Review 2009; 1: 139 [134].
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Most of the molecular studies on PAH have been per-
formed in IPAH and connective tissue disease-associated
PAH. Many of the pathological lesions manifest as an imbal-
ance between the proliferation and death of vascular cell ele-
ments [35]. Elements of abnormal cell proliferation include
clonality, loss of tumour suppression, and germline mutations
in familial disease, speciﬁcally in the bone morphogenic pro-
tein receptor type 2 (BMPR-2). Pathological endothelial cells
also display resistance to normal cell death through apopto-
sis [36]. Remarkably, these characteristics are all highly sug-
gestive of neoplasia [37–39]. It is unclear at this time what
the roles of BMPR-2, clonality and dysregulated proliferation
are in schistosomiasis-associated PAH.
The pathology of schistosomiasis-associated PAH is
unique, in that a dark pigment is commonly seen adjacent to
vascular lesions (see example in Fig. 2d). The aetiology of
this pigment is not known, but may represent either debris
left from the parasite or remnants of the host response.
Whole ova surrounded by granulomatous inﬂammation are
rarely seen.
Schistosomiasis, inﬂammation and PAH
The pathology associated with schistosomiasis is mostly
attributed to the intense granulomatous inﬂammation and
subsequent ﬁbrosis induced by parasite eggs that become
trapped in host organs.
The primary response is caused by migrating parasites in
the circulatory system, and shows characteristics of a type 1
T-cell response (Th1)—production of proinﬂammatory cyto-
kines such as interleukin (IL)-1 [6,7,40], IL-12 [41–44], inter-
feron-c (INF-c) [6,45], transforming growth factor-b (TGF-b)
[42,46] and tumour necrosis factor-a (TNF-a) [7,41]. They
may modulate the release of chemokines such as CXCL2,
CXCL5, CXCL9, CXCL10, CXCL11, CXCL22, CCL3,
CCL7, CX3CR1, RANTES and lymphotactin (XCL1) [2].
The secondary response is caused by schistosome eggs
and egg-derived antigens, which are potent and independent
inducers of the type 2 T-cell response (Th2). Transition to
the Th2 response occurs approximately 8 weeks post-trans-
fection, and is characterized by secretion of IL-4 [2,43,47],
IL-5 [48], IL-10 [49,50] and IL-13 [45,51,52].
Although Th2-mediated pathology is ultimately detrimen-
tal to the host, it is also clear that granulomas serve an
important host-protective function during infection. In
chronically infected hosts, schistosome eggs provide a
chronic antigenic stimulus for the immune response [52]. If
these antigens are not sequestered or neutralized effec-
tively, they may damage host tissues, the liver being particu-
(a) (b)
(c) (d)
FIG. 2. Representative pulmonary
pathology from a patient who died of
schistosomiasis-associated pulmonary
arterial hypertension. (a) Medial hyper-
trophy (arrows). (b) Plexiform lesion
(white arrowheads). (c) Eccentric intimal
thickening (black arrowheads) and a
dilated or angiomatoid lesion (star). (d)
Pigment (white arrows) adjacent to inti-
mal thickening (black arrowheads). All
scale bars are 100 lm.
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larly sensitive [52–54]. CD4+ T-cells are essential for granu-
loma formation, and early studies examining the respective
roles of Th1-associated and Th2-associated cytokines
showed that the granulomatous response evolves from an
early Th1-type to a sustained and dominant Th2-type cyto-
kine response [55–57]. Granuloma formation therefore
occurs in an environment that is initially proinﬂammatory
and type 1-like, but switches rapidly to one that is predomi-
nantly type 2-like.
Interestingly, recent reports have suggested that inﬂamma-
tion plays an important role in pulmonary hypertension.
T-cells, B-cells, mast cells, macrophages and dendritic cells,
as well as inﬂammatory cytokines and chemokines, were
identiﬁed in the lungs of patients with PAH, in remodelled
small pulmonary arteries including plexiform lesions. Several
cytokines, as well as receptors, are reported to be increased
in PAH patients [58–62], and cytokine antagonist therapy has
been tested with the experimental monocrotaline model of
PAH, including antagonists to IL-1 [63], RANTES [64], CCL2
[65] and CX3CR1 [66].
Little is known about the direct effects of Schistosoma
infection on the pulmonary vasculature, and more studies
need to be performed. A recent publication correlated cyto-
kines with pulmonary remodelling, and provided some new
insights on the topic [59]. Interestingly, some of the cyto-
kines were seen to be increased in a time-dependent man-
ner, in parallel with vascular changes and plexiform lesion
formation, whereas right ventricular hypertrophy was not
observed. Moreover, a signiﬁcant positive correlation
between the number of muscularized small peripheral vessels
and the lung egg burden was reported [59].
As inﬂammation is the main feature of Schistosoma infec-
tion and plays a role in the pulmonary vasculature as well,
correlation of different cytokines with schistomiasis and PAH
is characterized below.
IL-1, a proﬁbrotic cytokine secreted by monocytes and
macrophages, is released in the early stages of Schistosoma
infection [40]. On the other hand, an IL-1 antagonist was
shown to lower pulmonary artery pressure in acute respira-
tory distress syndrome associated with PAH in a piglet
model [67], whereas an IL-1 receptor antagonist reduced
pulmonary artery pressure and right heart hypertrophy in
monocrotaline-treated rats [63].
IL-4 is one of the major Th2 cytokines that stimulates
proliferation of activated B-cells and controls the release of
other cytokines. Its important role was demonstrated in
many studies in which IL-4 levels increased after infection
[68–70]. Moreover, administration of IL-4 with schistosome
eggs led to increased granuloma size, whereas anti-IL-4
treatment or IL-4 knockdown suppressed granuloma
formation and hepatic ﬁbrosis [43,47,51]. Concerning the
lungs, the role of IL-4 role is mostly clearly shown for
asthma [71,72]. The role of IL-4 in PAH is less clear, but
IL-4 can potentiate pathogenic autoreactive B-cells, which
are present in the plexiform lesions in some models and
may produce anti-endothelial antibodies [73,74]. In a recent
study, it was demonstrated that IL-4 levels increase in a
time-dependent manner after Schistosoma infection in a
murine model of PAH [59]. It was also reported that the
severity of pulmonary arterial remodelling was correlated
with the levels of IL-4 in bronchoalveolar lavage ﬂuid [75].
IL-5 was reported to participate in the maturation of
eosinophils and in tissue eosinophilia associated with Schisto-
soma infection [48]. It has been suggested that different
variants of the IL-5 gene region may modulate the immune
response to Schistosoma infection [69]. With respect to
PAH, the effect of IL-5 may be similar to that of IL-4, and
the severity of pulmonary arterial remodelling correlates
with the levels of IL-5 in bronchoalveolar lavage ﬂuid in a
murine model [75].
IL-6 acts as both a proinﬂammatory and an anti-inﬂamma-
tory cytokine, and is secreted by T-cells and macrophages to
stimulate the immune response. It was reported that Schisto-
soma infection induces IL-6 secretion in vitro in human and
mouse lung microvascular endothelial cells, as well as in vivo
in the pulmonary microvasculature in mice [76]. IL-6 corre-
lates with the development and progression of pulmonary
vascular remodelling [59], and has been shown to be propro-
liferative [77,78].
A major function of IL-10 is to limit and ultimately ter-
minate inﬂammatory responses, effectively controlling
immune responses and tolerance in vivo. The levels of IL-10
have been demonstrated to be elevated in schistosomiasis
patientsand to be associated with the inhibition of ﬁbrosis,
owing to IL-10’s antiﬁbrotic and anti-inﬂammatory effects
[50,53,68,70,79]. In mice infected with Schistosoma, IL-10
levels increase in a time-dependent manner, in parallel with
vascular remodelling [59]. Additionally, when overexpressed,
IL-10 signals via haem oxygenase-1. IL-10 has been reported
to reduce mean pulmonary artery pressure and the remod-
elling effect of monocrotaline-induced PAH, as well to inhi-
bit the proliferation of cultured human pulmonary artery
smooth muscle cells (PASMCs) [80].
IL-13 is known to induce physiological changes in parasit-
ized organs that eliminate the offending organisms or their
products. IL-13 has been reported to be induced after Schis-
tosoma infection [45,51,52,59,69], and several studies per-
formed in mice using IL-13 suppression [81] and inhibition
[82], demonstrated decreased inﬂammation after Schistosoma
infection. In the lung, depletion of IL-13 signiﬁcantly
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ameliorated pulmonary arterial muscularization in mice
exposed to inhaled Aspergillus [75] and was reported to pre-
vent emphysema and pulmonary inﬂammation. Moreover, IL-
13 stimulates PASMC migration, which is probably signiﬁcant
in vascular remodelling [59].
The IFN-c level is elevated after Schistosoma infection
[68,68,70]. IFN-c is associated with protection against
ﬁbrosis [79]. IFN-c was reported to induce human PASMCs
to release endothelin-1, which is a potent vasoconstrictor
and comitogen for vascular smooth muscle [83]. IFN-c pro-
duced at high levels in inﬂammation acts on endothelial cells
to modulate the evolution of the inﬂammatory response and
endothelial damage [84].
TGF-b is a multifunctional cytokine that controls prolifera-
tion, cellular differentiation [85,86] and other functions in
many cells. It is known to play a role in immunity [50,87], can-
cer [86,87], heart disease and ﬁbrosis [86]. In schistosomiasis,
TGF-b suppresses hepatic inﬂammation, whereas TGF-b
blockade signiﬁcantly increases the production ofIL-4, IL-6,
IL_17, TNF-a and IFN-c [46,50], as well as neutrophilia [50]. It
has been reported that TGF-b levels are elevated in PAH
patients [88]. Moreover, genetic mutations in members of the
TGF-b receptor superfamily, mostly BMPR-2, are observed in
patients with familial PAH and are associated with changes in
the structure of the lung vasculature [89–93]. Additionally,
TNF-a, IL-1b and IL-10 levels correlate with pulmonary vascu-
lar changes in Schistoma-infected mice [59].
Pulmonary Vascular Diseases Associated
with Other Parasitic Diseases
Wuchereria bancrofti (Filaria) is a parasitic ﬁlarial nematode
worm spread by mosquitoes. It largely affects areas across the
broad equatorial belt (Africa, Turkey, India, Southeast Asia,
Philippines, Oceanic Islands, Australia and parts of South
America). If the W. bacrofti infection is left untreated, it can
develop into a chronic disease called elephantiasis [94,95].
Filarial worms are known to cause PAH in animals, and it
has been shown that this disease may also cause human PAH
[96–99]. Many studies in dogs suggest that Diroﬁlaria immitus
(heartworm) is the cause of pulmonary diseases, and its
effect on pulmonary arterial pressure has been noted [100–
103], as well as its effect on lesion formation [102]. It has
also been demonstrated that chronic mild interstitial lung
disease persists in tropical pulmonary eosinophilia [104].
W. bancrofti can also cause acute or refractory bronchial
asthma [105]. Current therapy for ﬁlariasis includes treat-
ment with albendazole, ivermectin, doxycline and diethylcar-
bamazine [106–110].
Clonorchis sinensis lives in the liver of humans, and is found
mainly in the common bile duct and gall bladder, feeding on
bile. C. sinensis is endemic in Japan, China, Taiwan and South-
east Asia. A few cases of PAH have been associated with this
parasite [95].
Conclusions
Schistosomiasis is a common cause of PAH and a prototypi-
cal model for other inﬂammatory causes of PAH. The anti-
helminthic agent used for the treatment of schistosomiasis
is praziquantel, but it appears to have little effect on
patients with schistosomiasis-associated PAH after pro-
longed chronic infection [111]. The effects of more conven-
tional PAH therapies on schistosomiasis have been very
poorly investigated.
Phosphodiesterase (PDE) inhibitors are currently used to
treat PAH [112–114], and the PDE5 inhibitors sildenaﬁl and
tadalaﬁl are in clinical use [115–119]. PDE and its inhibitors
have been reported to affect schistosomes [120–122], which
could also be a promising targets. Small studies have sug-
gested that PDE5 inhibitors can be effective in treating schis-
tosomiasis-associated PAH (Loureiro et al., American Heart
Association, 2004, Abstract No. 2659, pp. III-572) [123].
Recent reports have suggested that tyrosine kinase (TK)
inhibitors could have anti-remodelling effects and also
reverse the PAH changes [124–129]. Interestingly, effects of
TKs on adult schistosomes have been reported, and some
studies have suggested that TKs directly affect adult worms
[130–133].
The pathogenic mechanism by which the combination of
the parasite’s effect on the host and the host’s immune
response to the parasite results in PAH remains largely
unknown at this time. Further basic science and clinical
research is necessary to determine elements of this process
that could be amenable to future treatments for Schistosoma
infection in general and schistoschomiasis-associated PAH
speciﬁcally. In particular, agents directed at blocking or
reversing inﬂammation caused by the parasite antigens and
proliferation of vascular elements may be required for com-
plete treatment of the disease.
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